SOD2 and gastric cancer: Involving 2,141 participants, GClnc1 was significantly upregulated in gastric cancer tissues and circulating exosomes, outperforming traditional biomarkers (CEA, CA72-4, CA19-9) with high sensitivity (>85%) and specificity (>78%) in validation cohorts.